AzTrials
AzTrials

Uterine Cervical NeoplasmsEVITA LATAMNCT04947605

Epidemiological Landscape of Cervical Cancer in Latin America

An observational study of Uterine Cervical Neoplasms, run by Latin American Cooperative Oncology Group at 12 sites in 4 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

A portrait of clinical and epidemiological aspects of cervical cancer in Latin America is required to understand the high frequency of cervical cancer despite the existence of effective preventive tools. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Uterine Cervical Neoplasms
How many people
524 participants
Where
12 sitesin 4 countries
Study dates
4 Nov 2021to Dec 2027
How long will I take part?
5 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: Data from approximately 482 patients are planned to be collected in 7 (seven) countries in Latin America. Enrollment period for data collection is planned to be 18 months and follow-up data will be recorded for 5 years. Patients will receive treatment and clinical assessments for cervical cancer as determined by their treating physician, according to the standard of care and routine clinical practice at each site.

Who may be able to join

  • Women > 18 years.
  • Histologically proven cervical carcinoma
  • Diagnosis of carcinoma of the cervix since January 2018 or newly diagnosis or recurrent disease during the period of study recruitment.
  • Any histology of cervical cancer at time of diagnosis.
  • FIGO stage IB2-IVA
  • Have available and adequate medical records for data collection
  • Accept to participate in the project and sign the informed consent (if applicable)

Who cannot join

  • FIGO stage I and IB1
  • Non-invasive cervical cancer
  • Synchronous tumor or second primary tumor in the last five years (exception for thyroid cancer or skin cancer non melanoma)

Trial locations and contacts

12 sites in 4 countries.

12 sites in 4 countries

Brazil8 sites

  • Hospital de Amor de Barretos

    Barretos, São Paulo, 14784-400

  • Hospital Erasto Gaertner

    Curitiba, Paraná, 81520-060

  • CRIO - Centro Regional Integrado de Oncologia

    Fortaleza, Ceará, 60335-480

  • CPO - Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS

    Porto Alegre, Rio Grande do Sul, 90610-000

  • INCA - Instituto Nacional de Câncer

    Rio de Janeiro, Rio de Janeiro, 20230-130

  • ICESP - Instituto do Câncer do Estado de São Paulo

    São Paulo, São Paulo, 01246-000

  • Pérola Centro de Pesquisa em Oncologia

    São Paulo, São Paulo, 01317-904

  • BP - A Beneficência Portuguesa de São Paulo

    São Paulo, São Paulo, 01323-001

Other trials in Brazil

Argentina2 sites

  • Sanatorio de La Mujer

    Rosario, Santa Fe Province

  • Centro Medico San Roque Exelsus

    San Miguel de Tucumán, Tucumán Province

Other trials in Argentina

Dominican Republic1 site

  • INCART - Instituto Nacional del Cáncer Rosa Emilia Sánchez Pérez de Tavares

    Santo Domingo, Grande Santo Domingo

Other trials in Dominican Republic

Peru1 site

  • Instituto Nacional de Enfermedades Neoplásicas (INEN)

    Lima, Peru

Other trials in Peru

About this study

Official title: Epidemiological Landscape of Cervical Cancer in Latin America .

A portrait of clinical and epidemiological aspects of cervical cancer in Latin America is required to understand the high frequency of cervical cancer despite the existence of effective preventive tools. A better understanding of the current situation of this scenario will provide a valuable groundwork for the development of national and cooperative programs to improve cervical cancer prevention and treatment.

Keywords
Cervical Neoplasms
Medical subject headings
Uterine Cervical Neoplasms

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. - Summarize the histologic subtype

    Summarize the histologic subtype, assessed by the anatomopathological assay of the tumor sample and the stage at diagnosis, assessed by FIGO stage (International Federation of Gynecology and Obstetrics (FIGO) staging of cancer of the cervix uteri - 2018), using gynecological exam. Image studies and TNM stage (AJCC 8th edition) will also be used to assess stage at diagnosis when available.

    Measured: January of 2028

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Jul 2021
  2. Study start4 Nov 2021
  3. Primary completion31 Mar 2023
  4. Study completionDec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
524 participants (actual)
Target duration
5 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT04947605
Sponsor's protocol ID
LACOG 0820
Acronym
EVITA LATAM
Status last verified
Aug 2026
First submitted
24 Jun 2021
Last updated
27 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.

    PubMed 30207593

  • Renna Junior NL, Silva GAE. Temporal trend and associated factors to advanced stage at diagnosis of cervical cancer: analysis of data from hospital based cancer registries in Brazil, 2000-2012. Epidemiol Serv Saude. 2018;27(2):e2017285. doi: 10.5123/s1679-49742018000200003. Epub 2018 May 7. English, Portuguese.

    PubMed 29742234

  • Nogueira-Rodrigues A. HPV Vaccination in Latin America: Global Challenges and Feasible Solutions. Am Soc Clin Oncol Educ Book. 2019 Jan;39:e45-e52. doi: 10.1200/EDBK_249695. Epub 2019 May 17.

    PubMed 31099692

  • Soneji S, Fukui N. Socioeconomic determinants of cervical cancer screening in Latin America. Rev Panam Salud Publica. 2013 Mar;33(3):174-82. doi: 10.1590/s1020-49892013000300003.

    PubMed 23698136

  • Lou H, Villagran G, Boland JF, Im KM, Polo S, Zhou W, Odey U, Juarez-Torres E, Medina-Martinez I, Roman-Basaure E, Mitchell J, Roberson D, Sawitzke J, Garland L, Rodriguez-Herrera M, Wells D, Troyer J, Pinto FC, Bass S, Zhang X, Castillo M, Gold B, Morales H, Yeager M, Berumen J, Alvirez E, Gharzouzi E, Dean M. Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway. Clin Cancer Res. 2015 Dec 1;21(23):5360-70. doi: 10.1158/1078-0432.CCR-14-1837. Epub 2015 Jun 16.

    PubMed 26080840

  • Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, Pruitt SK, Leary A. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019 Jun 10;37(17):1470-1478. doi: 10.1200/JCO.18.01265. Epub 2019 Apr 3.

    PubMed 30943124

  • Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014 Feb 20;370(8):734-43. doi: 10.1056/NEJMoa1309748.

    PubMed 24552320

  • Cancer Genome Atlas Research Network; Albert Einstein College of Medicine; Analytical Biological Services; Barretos Cancer Hospital; Baylor College of Medicine; Beckman Research Institute of City of Hope; Buck Institute for Research on Aging; Canada's Michael Smith Genome Sciences Centre; Harvard Medical School; Helen F. Graham Cancer Center &Research Institute at Christiana Care Health Services; HudsonAlpha Institute for Biotechnology; ILSbio, LLC; Indiana University School of Medicine; Institute of Human Virology; Institute for Systems Biology; International Genomics Consortium; Leidos Biomedical; Massachusetts General Hospital; McDonnell Genome Institute at Washington University; Medical College of Wisconsin; Medical University of South Carolina; Memorial Sloan Kettering Cancer Center; Montefiore Medical Center; NantOmics; National Cancer Institute; National Hospital, Abuja, Nigeria; National Human Genome Research Institute; National Institute of Environmental Health Sciences; National Institute on Deafness &Other Communication Disorders; Ontario Tumour Bank, London Health Sciences Centre; Ontario Tumour Bank, Ontario Institute for Cancer Research; Ontario Tumour Bank, The Ottawa Hospital; Oregon Health &Science University; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center; SRA International; St Joseph's Candler Health System; Eli &Edythe L. Broad Institute of Massachusetts Institute of Technology &Harvard University; Research Institute at Nationwide Children's Hospital; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; University of Bergen; University of Texas MD Anderson Cancer Center; University of Abuja Teaching Hospital; University of Alabama at Birmingham; University of California, Irvine; University of California Santa Cruz; University of Kansas Medical Center; University of Lausanne; University of New Mexico Health Sciences Center; University of North Carolina at Chapel Hill; University of Oklahoma Health Sciences Center; University of Pittsburgh; University of Sao Paulo, Ribeir ao Preto Medical School; University of Southern California; University of Washington; University of Wisconsin School of Medicine &Public Health; Van Andel Research Institute; Washington University in St Louis. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017 Mar 16;543(7645):378-384. doi: 10.1038/nature21386. Epub 2017 Jan 23.

    PubMed 28112728

Questions about this trial

What is this clinical trial studying?

An observational study of Uterine Cervical Neoplasms, run by Latin American Cooperative Oncology Group at 12 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 27 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 12 sites in Brazil, Argentina, Dominican Republic, Peru. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

- Summarize the histologic subtype (time frame: January of 2028). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04947605, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2026; AzTrials last refreshed its copy on 8 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in